Targeting MYD88-Mutant DLBCL with IRAKIMiDs: A Comparison to IRAK4 Kinase Inhibition and Evaluation of Synergy with Rational Combinations Case Study
Targeting MYD88-Mutant DLBCL with IRAKIMiDs: A Comparison to IRAK4 Kinase Inhibition and Evaluation of Synergy with Rational Combinations Case Study
9 PagesNovel heterobifunctional degraders that target both IRAK4 and IMiDbiology (IRAKIMiDs) leads to potent cell kill in DLBCL cell line models. IRAKIMiDsinduced superior cellular toxicity compared to IRAK4 kinase inhibition as determined by lower IC50s and induction of apoptosis. MYD88-mutated ABC-DLBCL cell lines are more sensitive to IRAKIMiDexposure as compared to wild type.
